T2 Biosystems Inc. 8-K Filing Report: Key Insights for December 30, 2024

Based on the provided section of the financial report, here are the key information and insights extracted:

1. Company Identifier:

• Name: T2 Biosystems, Inc.
• CIK: 0001492674
• State of Incorporation: Delaware (DE)
• SEC File Number: 001-36571
• EIN: 20-4827488

2. Address:

• Location: 101 Hartwell Avenue, Lexington, MA 02421
• Phone Number: (781) 761-4646

3. Stock Information:

• Type of Stock: Common stock
• Par Value: $0.001 per share
• Ticker Symbol: TTOO
• Exchange: NASDAQ

4. Filing Details:

• Form Type: 8-K
• Filing Date: December 30, 2024

5. Reporting Period:

• The reporting period is a single day, specifically December 30, 2024.

6. XML/XBRL Information:

• The document is formatted in XBRL (eXtensible Business Reporting Language), which is commonly used for SEC filings to facilitate automated analysis and reporting.

Insights:

• The filing date of December 30, 2024, indicates that this report contains information that is relevant to investors and stakeholders for that specific date.
• The company operates in a biotech space, indicated by its name, and is listed on NASDAQ, which may suggest it is under regulatory scrutiny and subject to the requirements of public company reporting.
• The common stock has a very low par value, which may indicate a strategy focused on raising capital through the issuance of shares.
• The report's submission on an 8-K form suggests that it may contain significant events or corporate changes that require immediate disclosure to the public and investors.

This section provides a snapshot of T2 Biosystems, Inc.'s corporate identity, stock details, and the nature of its SEC filing, which is crucial for potential investors and analysts tracking the company's performance and compliance.